24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Mapping IDs Geographic Access Barriers for Diabetic RetinopathyNormal Meal Tolerance Test Is Practical, Reliable in T2DMNo Link to Cognition in Diabetes Prevention Program StudySuicide by Insulin?Promising Start for National Diabetes Prevention ProgramDiabetes Drug Gets FDA Warning Due to Amputation RiskAngela Bassett Puts the Spotlight on Heart HealthAs Temps Rise, Risk of Pregnancy Complication May TooPharmacist-Involved Collaborative Care Benefits T2DMNever Breastfeeding Linked to Increased Risk of T1DMBioengineered Intraabdominal Endocrine Pancreas FeasibleBiomarker ID'd for Pregnancy-Induced Glucose IntoleranceTransplant of Insulin-Producing Cells Offers Hope Against Type 1 DiabetesVitamin D Doesn't Impact Insulin Sensitivity, Secretion in T2DMPCSK9 Linked to New-Onset Diabetes After Renal TransplantLinear Association for Weight Loss, HbA1c Reduction in T2DMHealth Tip: Make Food More FlavorfulAntioxidant Resveratrol May Help Reduce Arteriosclerosis in T2DMHealth Tip: Create a Sick-Day Plan for DiabetesRed Wine Antioxidant Might Help Diabetics' ArteriesCardiometabolic Disease Staging Score Quantifies Diabetes RiskIntense Interval Training Cuts Hypoglycemia Awareness in T1DMDecreased Cortical Thickness Seen in Type 2 DiabetesAlgorithm Integrated Into App Forecasts Glucose LevelsThree Anti-VEGF Treatments Effective for Diabetic RetinopathyType 2 Diabetes May Be Bad for Brain HealthHealth Tip: Coping With the 'Dawn Phenomenon'Plasma Uric Acid Lowering Tied to Drop in Systolic BP in T1DMHealth Tip: Continuous Glucose Monitoring DevicesT2DM Risk Cut by Variant in Sulfonylurea Receptor EncoderObesity Quadruples Kids' Type 2 Diabetes Risk: StudyDoctors Encouraged to Assess Driving Risks for T1DM PatientsEarly Glycemic Control With Metformin Cuts CVD EventsWhen Is It Safe to Drive With Type 1 Diabetes?Nurse-Led Intervention Helps With Diabetes ControlIs Annual Eye Exam a Must for People With Type 1 Diabetes?RUNX1 May Play Role in Proliferative Diabetic RetinopathyFast-Acting Insulin Aspart Ups Glycemic Control in T1DMDiabetes Continues to Be a Significant Public Health BurdenContinuous Glucose Monitoring Improves Quality of Life in T1DMDiabetes Continues Its Relentless RiseContinuous Subcutaneous Insulin Infusion Bests Injections in T2DMPrevalence of Metformin Use 0.7 Percent in PrediabetesENDO: Distinct Urine Metabolite Profile in Obese Youth With T2DMRace Plays Role in Heart, Diabetes Risk, Even at Normal WeightPredictive Low-Glucose Mgmt Cuts Hypoglycemic Events in T1DTeleretinal Diabetic Retinopathy Screening Ups Screening RatesDAPT Cessation Patterns Vary With Diabetes Status After PCIIncreased Use of Newer Meds for Diabetic Nephropathy in the U.S.What Drugs Work Best for Diabetic Nerve Pain?
Links
Related Topics

Medical Disorders

Early Glycemic Control With Metformin Cuts CVD Events


HealthDay News
Updated: Apr 21st 2017

new article illustration

FRIDAY, April 21, 2017 (HealthDay News) -- For patients with type 2 diabetes who initiate metformin, early achievement of low hemoglobin A1c (HbA1c) is associated with a reduction in the subsequent risk of cardiovascular events or death, according to a study published online April 12 in Diabetes Care.

Elisabeth Svensson, Ph.D., from Aarhus University Hospital in Denmark, and colleagues conducted a population-based study involving 24,572 metformin initiators with HbA1c tests in Northern Denmark from 2000 to 2012 (median follow-up, 2.6 years). Patients were classified by HbA1c achieved at six months after metformin initiation and by the magnitude of change in HbA1c from the pretreatment base.

The researchers found that, compared with a target HbA1c of <6.5 percent, the risk of a combined outcome event (acute myocardial infarction, stroke, or death) increased gradually with increasing levels of HbA1c achieved (adjusted hazard ratios, 1.18 for 6.5 to 6.99 percent; 1.23 for 7.0 to 7.49 percent; 1.34 for 7.5 to 7.99 percent, and 1.59 for ≥8 percent). Outcome was also predicted by a large absolute HbA1c reduction from baseline (adjusted hazard ratio, 0.80 for Δ = −4, compared with no change [Δ = 0]).

"A large initial HbA1c reduction and achievement of low HbA1c levels within six months after metformin initiation are associated with a lower risk of cardiovascular events and death in patients with type 2 diabetes," the authors write.

Several authors disclosed financial ties to Novo Nordisk, which partially funded the study.

Abstract
Full Text